Insmed to Host Analyst and Investor Day on July 19, 2017
The agenda will include an overview of the Company's development and pre-commercial plans for Amikacin Liposome Inhalation Suspension (ALIS), as well as an introduction to the Company's Phase 2 candidate INS1007.
The program will also feature a presentation by Dr.
The event will be webcast live and can be accessed by visiting the investor relations section of the company's website at www.insmed.com. The webcast will be archived for a period of 90 days following the conclusion of the live event.
"Insmed" and "ARIKAYCE" are the company's trademarks. All other trademarks, trade names or service marks appearing in this press release are the property of their respective owners.
Laura Perryor Heather Savelle Argot Partners212-600-1902 firstname.lastname@example.org email@example.com
News Provided by Acquire Media